General
Preferred name
vildagliptin
Synonyms
Vildagliptin dihydrate ()
LAF237 dihydrate ()
NVP-LAF 237 dihydrate ()
LAF237 ()
NVP-LAF 237 ()
Vildagliptin (LAF-237) ()
Vildagliptin-d7 ()
NVP-LAF237 ()
Xiliarx ()
LAF 237 ()
Galvus ()
Equa ()
Vildagliptine ()
Vildagliptina ()
Vitagliptin ()
LAF-237 ()
Jalra ()
P&D ID
PD009355
CAS
274901-16-5
1133208-42-0
Tags
available
covalent binder
drug
Approved by
EMA
First approval
2007
Drug indication
Type-2 diabetes
diabetes mellitus
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor class anti-diabetic drug. (GtoPdb)
Cell lines
1
Organisms
0
Compound Sets
24
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CovalentInDB
CZ-OPENSCREEN Bioactive Library
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
External IDs
70
Properties
(calculated by RDKit )
Molecular Weight
303.19
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
5
Aromatic Ring Count
0
cLogP
1.17
TPSA
76.36
Fraction CSP3
0.88
Chiral centers
3.0
Largest ring
6.0
QED
0.82
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Dipeptidyl Peptidase
Ferroptosis
DPP4 inhibitor
DPP
Pathway
Metabolic Enzyme/Protease
Apoptosis
Source data